ISSN 1662-4009 (online)

ey0020.3-1 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.1. Safety and efficacy of denosumab for fibrous dysplasia of bone

LF de Castro , Z Michel , K Pan , J Taylor , V Szymczuk , S Paravastu , B Saboury , GZ Papadakis , X Li , K Milligan , B Boyce , SM Paul , MT Collins , AM Boyce

In Brief: This phase 2 study investigated the effect of the RANKL inhibitor denosumab on fibrous dysplasia lesion activity, as well as the rebound in bone turnover after treatment discontinuation.Commentary: Denosumab is a humanized monoclonal antibody that inhibits RANKL with potent but transient antiosteoclastic effects, and discontinuation of denosumab treatment is associated with a rebound in bone turnover. In this study, eight women received high do...

ey0020.9-7 | Genetic Obesity and Genetic Risk Score | ESPEYB20

9.7. Rare antagonistic leptin variants and severe, early-onset obesity

JB Funcke , B Moepps , J Roos , J von Schnurbein , K Verstraete , E Frohlich-Reiterer , K Kohlsdorf , A Nunziata , S Brandt , A Tsirigotaki , A Dansercoer , E Suppan , B Haris , KM Debatin , SN Savvides , IS Farooqi , K Hussain , P Gierschik , P Fischer-Posovszky , M Wabitsch

Brief summary: The authors provide the first description of antagonistic hormone mutations as the cause of congenital disease in humans. The paper describes detailed characterizations of two novel, antagonistic leptin mutations underlying a formerly unrecognized form of congenital leptin dysfunction and delineate the challenges these mutations pose to the diagnosis and therapy of the disease.After the initial description of biologically inactive leptin v...

ey0018.5-10 | Translational highlights | ESPEYB18

5.10. Single cell transcriptomic analysis of human pluripotent stem cell chondrogenesis

Wu Chia-Lung , Dicks Amanda , Steward Nancy , Tang Ruhang , Katz Dakota B , Choi Yun-Rak , Guilak Farshid

Nat Commun. 2021 Jan 13;12(1):362 Abstract: https://pubmed.ncbi.nlm.nih.gov/33441552/In brief: Heterogenous differentiation patterns and low yields limit the use of human induced pluripotent stem cells (hiPSCs) for the generation of cartilage. In the present work, bulk- and single cell RNA sequencing during chondrogenic differentiation were used to identify regulatory networks resp...

ey0019.1-12 | Clinical Papers | ESPEYB19

1.12. Dysgenesis and Dysfunction of the Pancreas and Pituitary Due to FOXA2 Gene Defects

SB Kaygusuz , Ates E Arslan , ML Vignola , B Volkan , BB Geckinli , S Turan , A Bereket , C Gaston-Massuet , T Guran

J Clin Endocrinol Metab. 2021, 106(10):e4142-e4154. doi: 10.1210/clinem/dgab352. PMID: 33999151.Brief Summary: The authors show that patients with hypopituitarism and FOXA2 gene defects also need screening for dysfunction of the pancreas.The Forkhead box A2 transcription factor (FOXA2) is important for normal development of the central nervous system, i...

ey0019.5-14 | Translational highlights | ESPEYB19

5.14. Fibrillin-1 deficiency in the outer perichondrium causes longitudinal bone overgrowth in mice with Marfan syndrome

L Sedes , E Wondimu , B Crockett , J Hansen , A Cantalupo , K Asano , R Iyengar , D.B Rifkin , S Smaldone , F Ramirez

Hum Mol Genet ddac107 (2022)Abstract: https://pubmed.ncbi.nlm.nih.gov/35567544/In Brief: Disproportionate tall stature represents a hallmark feature of Marfan syndrome, although specific mechanisms underlying linear bone overgrowth are unclear. This study used an ex vivo model system to identify dysregulation of TGFβ-binding proteins in the outer perichondrium as causative for the bon...

ey0019.9-3 | Metabolic risk in childhood cancer | ESPEYB19

9.3. Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies

S Welsch , K Sawadogo , B Brichard , Ville de Goyet M de , Damme A Van , C Boulanger , P Lysy

sophie.welsch@uclouvain.be Diabet Med. 2022; 39: e14720. PMID: 34652870.Brief Summary: Childhood cancer survivors are at increased risk of hyperglycaemia and diabetes due to cancer treatments as asparaginase, steroids and total body irradiation. This single center, retrospective study analyzed the prevalence of hyperglycaemia in 267 patients treated between 2004 and 2019 for hematologic malignancie...

ey0017.8-21 | Reviews | ESPEYB17

8.21. P450 oxidoreductase deficiency: A systematic review and meta-analysis of genotypes, phenotypes, and their relationships

B Dean , GL Chrisp , M Quartararo , AM Maguire , S Hameed , BR King , CF Munns , DJ Torpy , H Falhammar , RL Rushworth

To read the full abstract: J Clin Endocrinol Metab. 2020; 105(3): dgz255. PMID: 31825489.P450 oxidoreductase deficiency (PORD) is a rare autosomal recessive variant of congenital adrenal hyperplasia (CAH) arising from homozygous or compound heterozygous mutations to the gene encoding the enzyme P450 oxidoreductase (POR ) (1). Patients with PORD have a range of skeletal malformation...

ey0017.9-3 | Fertility-Related Issues | ESPEYB17

9.3. The influence of different intensity of treatment on hormonal markers of gonadal function in acute lymphoblastic leukemia survivors

M Krawczuk-Rybak , M Płonowski , E Leszczyńska , E Latoch , M Sawicka-Żukowska , K Muszyńska-Rosłan , J Skalska-Sadowska , J Wachowiak , D Sga-Pondel , B Kazanowska , A Chybicka , T Stachowicz-Stencel , J Stefanowicz , I Malinowska , M Matysiak , A Kotan , M Wysocki , A Pobudejska-Piena¸żek , T Szczepański , B Przybyszewski , W Badowska , D Szymańska-Miller , JR Kowalczyk , E Kamieńska , T Urasiński , A Wawrzeńczyk , B Żelazowska-Rutkowska , B Cylwik

To read the full abstract: Hematol Oncol. 2019 Dec;37(5):609–616. mar26@mp.plAcute lymphoblastic leukaemia (ALL) is the most common childhood neoplasia with an actual survival rate >80%. ALL treatment has changed considerably during last 30 years; radiotherapy with 24 Gy to the central nervous system (CNS) has been eliminated or reduced to lower doses (12 or 18 Gy) and chemotherapy regimens are now tailo...

ey0017.9-6 | Fertility-Related Issues | ESPEYB17

9.6. Assessment of ovarian function in adolescents and young adults after childhood cancer treatment-How accurate are young adult/parent proxy-reported outcomes?

SA George , R Williamson Lewis , L McKenzie , B Cherven , BC Patterson , KE Effinger , AC Mertens , LR Meacham

To read the full abstract: Pediatr Blood Cancer. 2019;66(12):e27981. sgeorg4@emory.eduThis cross-sectional study tested the concordance between young adult (or parent proxy)-reported premature ovarian insufficiency (POI) and biochemical evidence of POI, defined as FSH ≥40 mIU/ml, in 182 childhood cancer survivors (CCS) who had received gonadotoxic therapy. Reported POI was defined as the survivor taki...

ey0017.9-10 | Premature Aging, Cardiometabolic Fitness and Cardiovascular Damage | ESPEYB17

9.10. Childhood leukemia survivors and metabolic response to exercise: A pilot controlled study

C Pegon , E Rochette , N Rouel , B Pereira , E Dore , F Isfan , V Greze , E Merlin , J Kanold , P Duche

To read the full abstract: J Clin Med. 2020 Feb 19;9(2). pii: E562. e_rochette@chu-clermontferrand.frThis 5-month prospective case-control study was designed to evaluate the impairment of metabolic response to exercise in 20 childhood acute leukaemia survivors (CALSs), by the analysis of substrate oxidation during submaximal exercise, in comparison with 20 matched healthy controls.<p cla...